PHAT

SEC source: 0001209191-21-035474 · doc4.xml · derivative · entry 1

Stenhouse Mark · CIK 0001734751 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-21-035458 · doc4.xml · derivative · entry 1

Yamada Tadataka · CIK 0001402530 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-21-035470 · doc4.xml · derivative · entry 1

COLA MICHAEL F · CIK 0001188940 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-21-035466 · doc4.xml · derivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001395064-21-000087 · wf-form4_162185185710054.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,011,137

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.21 to $36.14. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-035479 · doc4.xml · derivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 6

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,300,945

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.23 to $35.41. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 5

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,301,250

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.23 to $35.20. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,303,528

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.20 to $34.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001395064-21-000087 · wf-form4_162185185710054.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,022,785

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.33. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,304,427

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.32 to $33.49. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,307,656

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.30 to $33.28. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-035068 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,323,676

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.29 to $32.28. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001395064-21-000082 · wf-form4_162133212133123.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,029,883

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000078 · wf-form4_162098662739246.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,029,983

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000078 · wf-form4_162098662739246.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,030,083

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.18. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000078 · wf-form4_162098662739246.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,030,988

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.98. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000076 · wf-form4_162072902653681.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,041,859

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.10. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000060 · wf-form4_162038652477240.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,042,870

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.03. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000060 · wf-form4_162038652477240.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,043,072

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.91. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 5

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 765,700

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.7550 to $38.06. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 766,789

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.66 to $37.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 3

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 768,189

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to $36.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 7

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,050,008

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 6

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,050,108

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F7 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.04 to $37.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 5

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,053,608

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F6 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.93. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 4

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,058,298

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 2

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 770,157

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.97. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-030141 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 775,910

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.15 to $38.12. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,069,368

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $38.96 to $39.16. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,069,571

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $38.04 to $38.92. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000058 · wf-form4_162021757083358.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080,843

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.04 to $38.03. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 7

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,340,945

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.74 to $38.35. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 6

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,347,740

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.74 to $37.73. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 5

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,354,068

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.65 to $36.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 4

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,357,427

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.37. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 5

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 780,200

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.04 to $37.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 780,985

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.04 to $37.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 3

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 785,301

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $36.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,358,827

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.02 to $37.59. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,360,557

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $37.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025856 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,368,326

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $36.01. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 2

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 789,553

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 to $38.55. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-025456 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 791,295

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.73. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-022705 · doc4.xml · derivative · entry 4

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 855,687

Underlying: Common Stock · 11,513 shares

Expires 2029-08-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option was granted on August 29, 2019 and vested with respect to 25% of the shares of common stock on August 29, 2020, and thereafter vests in equal monthly installments over the following three years.

SEC source: 0001209191-21-022705 · doc4.xml · nonDerivative · entry 3

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-022705 · doc4.xml · nonDerivative · entry 2

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,140

F2 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.82 to $43.81. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-022705 · doc4.xml · nonDerivative · entry 1

Curran Terrie · CIK 0001690298 · Director · President and Chief Executive

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,513

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon exercising a stock option.

SEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 6

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,380,945

SEC source: 0001209191-21-020266 · doc4.xml · nonDerivative · entry 5

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,381,445

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $47.67. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.